Virtual Library
Start Your Search
Matteo Brunelli
Author of
-
+
P2.04 - Immuno-oncology (ID 167)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.04-51 - A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial (ID 1885)
10:15 - 18:15 | Author(s): Matteo Brunelli
- Abstract
Background
Genomic abnormalities detected in immune-escape/editing-related genes may promote immunotherapy resistance. In the light of this hypothesis, we designed the PRINCiPe (Predictors of Resistance to Immunotherapy with NIV) study in APNSCLC.
Method
FFPE-tumor blocks of APNSCLC pts undergone NIV were retrospectively sequenced for Somatic Mutations/Copy Number Variations (SM/CNV) (Ampliseq 17-genes customized panel: APLNR, B2M, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IRF9, JAK1, JAK2, JAK3, PIAS4, PTPN2, SOCS1, STAT1, STAT2, STAT3, TYK2). End-points of the PRINCiPe study were overall-, progression-free-survival (OS/PFS) and objective response rate (ORR).
Result
Forty-four APNSCLC pts were gathered (median age 69.5 yrs, median number of previous lines 3 [2-5], 2nd line NIV [75.0%], male/female 77.3/22.7%, squamous/non-squamous 31.8/68.2%, EGFR mutant 5 [11.4%], median follow-up 6.8 months [range 1-23], deaths 24 [54.5%]). JAK3/JAK2 (7/3 pts, 15.9/6.8%) CNV and IFNAR2 SM (4 pts, 9.1%) were the most frequent (>1 pts) abnormalities. Pts (n=15) with JAK3, PIAS4, PTPN2, STAT3, IFNAR2 SM and/or JAK2/3 CNV (IGS+) had a significantly lower PFS than those without (IGS-) (median PFS 2.8 vs. 6.6 months; p=0.006), while a trend towards significance was observed in terms of OS (median OS 5.1 vs. 13.0 months for IGS+ and IGS-, respectively; p=0.06 log-rank, p=0.05 Tarone-Ware). At multivariate analysis, IGS+ was independently associated with a shorter PFS (HR 2.64, 95% CI 1.3-5.4, p=0.008). IGS+ pts were significantly more probable to be affected by liver metastases than those without (p=0.01).
Conclusion
The identified IGS appears to select APNSCLC pts with a significant lower chance to benefit from NIV, supporting intrinsic resistance. A prospective larger and external validation is ongoing, as well as the comprehensive transcriptome analysis.